Recent disruptions have highlighted the urgent need for robust strategies to reduce supply chain risks and ensure the continuous delivery of vital treatments to waiting patients.
In this article, Jim Donovan (pictured), Vice President of Pfizer CentreOne, shares his unique insights derived from recent trends and examines the necessary steps that drug manufacturers must take to safeguard supply chain integrity.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
